ZA200502416B - Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-beta. - Google Patents

Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-beta. Download PDF

Info

Publication number
ZA200502416B
ZA200502416B ZA200502416A ZA200502416A ZA200502416B ZA 200502416 B ZA200502416 B ZA 200502416B ZA 200502416 A ZA200502416 A ZA 200502416A ZA 200502416 A ZA200502416 A ZA 200502416A ZA 200502416 B ZA200502416 B ZA 200502416B
Authority
ZA
South Africa
Prior art keywords
ifn
treatment
substance
composition
therapeutic
Prior art date
Application number
ZA200502416A
Other languages
English (en)
Inventor
Alfred Sandrock
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of ZA200502416B publication Critical patent/ZA200502416B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200502416A 2002-09-27 2005-03-23 Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-beta. ZA200502416B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41430702P 2002-09-27 2002-09-27

Publications (1)

Publication Number Publication Date
ZA200502416B true ZA200502416B (en) 2005-10-20

Family

ID=32043377

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200502416A ZA200502416B (en) 2002-09-27 2005-03-23 Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-beta.

Country Status (21)

Country Link
US (2) US20060182715A1 (enExample)
EP (1) EP1575531B9 (enExample)
JP (3) JP2006513990A (enExample)
KR (1) KR20050059195A (enExample)
CN (2) CN1802170A (enExample)
AT (1) ATE520412T1 (enExample)
AU (1) AU2003277006C1 (enExample)
BR (1) BR0314548A (enExample)
CA (1) CA2500189A1 (enExample)
DK (1) DK1575531T3 (enExample)
EA (1) EA009289B1 (enExample)
GE (1) GEP20094699B (enExample)
IS (1) IS7746A (enExample)
MX (1) MXPA05003243A (enExample)
NO (1) NO20052059L (enExample)
NZ (1) NZ565990A (enExample)
PL (1) PL377612A1 (enExample)
RS (1) RS20050255A (enExample)
UA (1) UA86749C2 (enExample)
WO (1) WO2004028472A2 (enExample)
ZA (1) ZA200502416B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1802170A (zh) * 2002-09-27 2006-07-12 比奥根艾迪克Ma公司 利用IFN－β治疗慢性炎性脱髓鞘性多神经病
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
EP2572734B1 (en) * 2006-10-31 2016-04-06 East Carolina University Cytokine-based fusion proteins for treatment of immune disorders
EP2413958A4 (en) 2009-03-31 2014-04-02 Univ East Carolina CYTOKINS AND NEUROANTIGENE FOR THE TREATMENT OF IMMUNE DISEASES
CN109134642A (zh) * 2011-10-01 2019-01-04 株式会社糖锁工学研究所 加成糖链的多肽及含有该多肽的医药组合物
GB201212878D0 (en) 2012-07-20 2012-09-05 Pike Justin Authentication method and system
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
GB201520741D0 (en) 2015-05-27 2016-01-06 Mypinpad Ltd And Licentia Group Ltd Authentication methods and systems
KR102454376B1 (ko) * 2018-07-04 2022-10-17 서울대학교산학협력단 신경손상의 면역세포치료
GB201916441D0 (en) 2019-11-12 2019-12-25 Mypinpad Ltd Computer-implemented system and method

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
DE3712564A1 (de) * 1987-04-14 1988-11-24 Bioferon Biochem Substanz Verfahren zur konstruktion einer animalen zellinie fuer die herstellung von humanem interferon-beta
DE4128319A1 (de) * 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type
TW403653B (en) * 1995-12-25 2000-09-01 Otsuka Pharma Co Ltd Dry compositions
EP2599503B1 (en) * 1998-10-16 2017-05-17 Biogen MA Inc. Polymer conjugates of interferon beta-1A and uses thereof
DK1121382T3 (da) * 1998-10-16 2006-11-13 Biogen Idec Inc Interferon-beta-fusionsproteiner og deres anvendelser
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
CA2363779A1 (en) * 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
AU2002212107A1 (en) * 2000-11-02 2002-05-15 Maxygen Aps New multimeric interferon beta polypeptides
MXPA03007619A (es) * 2001-02-27 2003-12-04 Maxygen Aps Nuevas moleculas similares a interferon beta.
AU2002254174A1 (en) * 2001-03-13 2002-09-24 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
CN1802170A (zh) * 2002-09-27 2006-07-12 比奥根艾迪克Ma公司 利用IFN－β治疗慢性炎性脱髓鞘性多神经病

Also Published As

Publication number Publication date
EA200500545A2 (ru) 2005-08-25
EA009289B1 (ru) 2007-12-28
EP1575531A2 (en) 2005-09-21
MXPA05003243A (es) 2005-09-12
RS20050255A (sr) 2007-08-03
EP1575531B9 (en) 2012-02-22
US20060182715A1 (en) 2006-08-17
NZ565990A (en) 2009-10-30
DK1575531T3 (da) 2011-11-21
WO2004028472A2 (en) 2004-04-08
JP2011132248A (ja) 2011-07-07
CN1802170A (zh) 2006-07-12
EP1575531A4 (en) 2008-01-23
AU2003277006B2 (en) 2009-09-10
JP2007039463A (ja) 2007-02-15
PL377612A1 (pl) 2006-02-06
ATE520412T1 (de) 2011-09-15
US20120058083A1 (en) 2012-03-08
GEP20094699B (en) 2009-06-10
KR20050059195A (ko) 2005-06-17
JP2006513990A (ja) 2006-04-27
CN102038938A (zh) 2011-05-04
NO20052059L (no) 2005-06-27
CA2500189A1 (en) 2004-04-08
NO20052059D0 (no) 2005-04-27
BR0314548A (pt) 2005-08-09
WO2004028472A3 (en) 2006-01-19
IS7746A (is) 2005-03-15
AU2003277006A1 (en) 2004-04-19
AU2003277006C1 (en) 2010-04-01
EP1575531B1 (en) 2011-08-17
UA86749C2 (en) 2009-05-25
EA200500545A3 (ru) 2007-04-27

Similar Documents

Publication Publication Date Title
US20120058083A1 (en) Therapies for Chronic Inflammatory Demyelinating Polyneuropathy Using Interferon-Beta
AU2003256603C1 (en) Therapies for renal failure using interferon-Beta
CN100480266C (zh) 干扰素-β融合蛋白及用途
ES2690147T3 (es) Apelina pegilada y usos de la misma
ZA200609412B (en) Hydrogel interferon formulations
EP3858866A1 (en) Glp1-fc fusion protein and conjugate thereof
JP2006513990A5 (enExample)
ES2381341T3 (es) Uso de activadores de gp130 en neuropatía diabética
JP2007525152A (ja) 変異ニューブラスチンのポリマー結合体
HK40048033A (en) Glp1-fc fusion protein and conjugate thereof
HK1141998A (en) THERAPIES FOR RENAL FAILURE USING INTERFERON-β